FDA Issues Complete Response Letter (CRL) for Corcept Therapeutics’ Relacorilant: Analysis and Pipeline Impact
December 31, 2025
What’s Next for Corcept Therapeutics After FDA’s CRL for Relacorilant as a
- April 1, 2026
FDA, EMA, and regulatory affairs
What’s Next for Corcept Therapeutics After FDA’s CRL for Relacorilant as a
The State of HCP Engagement 2026: Separating Vendor Hype from Commercial Reality
In today’s fast pharma scene, brands act. Customer talk must hit, feel
Artificial intelligence (AI) shifts U.S. healthcare. AI touches care, tests, and drug
The recent appointment of Richard Pazdur as the head of the FDA’s
Navigating the complex landscape of pharmaceutical development requires a deep understanding of
In the intricate world of pharmaceutical regulation, the intersection of politics and
November 21, 2025 HEADLINE FINDINGS: Alkermes escalates bidding war for Avadel Pharmaceuticals to
Redemplo (plozasiran) cleared for familial chylomicronemia syndrome at $60,000 annual price—ten times
Biotech prepares FDA submission despite failing key pain crisis endpoint; shares plummet
Agios Pharmaceuticals recently faced a substantial decline in its stock value following
BIOPHARMA EXECUTIVE INTELLIGENCE BRIEFING November 19, 2025 Headline Findings: Merck has announced
On November 18, 2025, Arrowhead Pharmaceuticals made a historic move by receiving
In a bold move aimed at revitalizing American pharmaceutical research, FDA Commissioner
The recent announcement from the White House about a new trade deal,
On November 14, 2025, the U.S. Food and Drug Administration (FDA) made
The landscape of cancer treatment is evolving, especially for patients battling acute
In a significant move, President Donald Trump recently signed a short-term government
Malaria remains one of the world’s deadliest infectious diseases, with millions of
In recent weeks, the U.S. Food and Drug Administration (FDA) has witnessed
